---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-296407"
form_type: "8-K"
ticker: "SPRO"
cik: "0001701108"
company_name: "Spero Therapeutics, Inc."
filed_at: "2021-10-12T23:59:59+00:00"
generated_at: "2026-06-28T21:32:25.128682+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Spero Therapeutics appoints Kathleen Tregoning to Board; Jean-François Formela resigns

## Summary
- Jean-François Formela resigned from the Board effective Oct 11, 2021, as part of a planned transition.
- Kathleen Tregoning appointed to fill the vacancy, effective Oct 11, 2021.
- Tregoning brings over 20 years of biotech and public policy experience; currently Chief Corporate Affairs Officer at Cerevel Therapeutics.
- Former executive at Biogen and Sanofi, and former congressional staff member.
- Tregoning will serve as Class III director up for reelection at 2023 annual meeting.

## SEC filing metadata
- accession: 0001193125-21-296407
- form_type: 8-K
- ticker: SPRO
- cik: 0001701108
- company_name: Spero Therapeutics, Inc.
- filed_at: 2021-10-12T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1701108/000119312521296407/0001193125-21-296407-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1701108/000119312521296407/d227095d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-296407
- JSON: https://secwatch.observer/filing/0001193125-21-296407.json
- Plain text: https://secwatch.observer/filing/0001193125-21-296407.txt

## Key facts
- Executive change
  Jean-François Formela resigned as Director at Spero Therapeutics, Inc..
  - Action: resigned
  - Role: Director
  source text: On October 11, 2021, Jean-François Formela, M.D. notified the Board of Directors (the “Board”) of Spero Therapeutics, Inc. (the “Company”) of his resignation from the Board and the Compensation Committee and Nominating and Corporate Governance Committee of the Board, effective as of October 11, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1701108/000119312521296407/0001193125-21-296407-index.htm
- Executive change
  Kathleen Tregoning was appointed as Director at Spero Therapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: On October 11, 2021, the Board, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Kathleen Tregoning to the Board, effective as of October 11, 2021, to fill the vacancy created by Dr. Formela’s resignation.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1701108/000119312521296407/0001193125-21-296407-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.